Je was op zoek naar: active control of the bending shape of smart b... (Deens - Engels)

i- beamthe shape of the cursor
i-beam

blokthe shape of the cursor, similar to a capital i
block

arrangements under the control of the court which involve the vesting of all or part of the property of the debtor in the official assignee for realisation and distribution
arrangements under the control of the court which involve the vesting of all or part of the property of the debtor in the official assignee for realisation and distribution

contribution to part s. 2. 3 of the structure of the dossier for applications for marketing authorisation ­ control of starting materials for the production of plasma-derived medicinal products
contribution to part s.2.3 of the structure of the dossier for applications for marketing authorisation ­ control of starting materials for the production of plasma-derived medicinal products

control of identification of the horse described in the passport the identity of the equine animal must be checked each time this is required by rules and regulations and certified that it conforms to the description given in section i of the passport. date
the identity of the equine animal must be checked each time this is required by rules and regulations and certified that it conforms to the description given in section i of the passport.

contribution to part s. 2. 3 of the structure of the dossier for applications for marketing authorisation – control of starting materials for the production of plasma- derived medicinal products
contribution to part s.2.3 of the structure of the dossier for applications for marketing authorisation – control of starting materials for the production of plasma-derived medicinal products

unless otherwise decided by the ecb 's governing council , the target2 compensation scheme shall not apply if the technical malfunction of target2 arises out of external events beyond the reasonable control of the cbs concerned or as a result of acts or omissions by third parties .
unless otherwise decided by the ecb 's governing council , the target2 compensation scheme shall not apply if the technical malfunction of target2 arises out of external events beyond the reasonable control of the cbs concerned or as a result of acts or omissions by third parties .

( b ) unless otherwise decided by the ecb 's governing council , the target2 compensation scheme shall not apply if the technical malfunction of target2 arises out of external events beyond the reasonable control of the cbs concerned or as a result of acts or omissions by third parties .
( b ) unless otherwise decided by the ecb 's governing council , the target2 compensation scheme shall not apply if the technical malfunction of target2 arises out of external events beyond the reasonable control of the cbs concerned or as a result of acts or omissions by third parties .

in this context, the european commission will promote cooperation between member states with a view to enhancing authorisation procedures for projects on trans-european energy networks and will promote technical cooperation projects between the operators responsible for the management, monitoring and control of the trans-european energy networks.
in this context, the european commission will promote cooperation between member states with a view to enhancing authorisation procedures for projects on trans-european energy networks and will promote technical cooperation projects between the operators responsible for the management, monitoring and control of the trans-european energy networks.

guidelines final eu recommendations for the influenza vaccine composition for the season 2000/2001 report of the emea expert workshop on human tses and plasma-derived medicinal products, 15-16 may 2000 concept paper on the development of a points to consider on xenogeneic cell therapy note for guidance on the production and quality control of animal immunoglobulins and immunosera for human use note for guidance on comparability of medicinal products containing biotechnology-derived proteins as active substances position statement on the use of tumorigenic cells of human origin for the production of biological and biotechnological medicinal products revision of section 3. 2. 5 of cpmp note for guidance on plasma-derived medicinal products points to consider on the reduction, elimination or substitution of thiomersal in vaccines
final eu recommendations for the influenza vaccine composition for the season 2000/2001 adopted april 2000 report of the emea expert workshop on human tses and plasma-derived medicinal products, 15-16 may 2000 adopted july 2000 concept paper on the development of a points to consider on xenogeneic cell therapy adopted november 2000 note for guidance on the production and quality control of animal immunoglobulins and immunosera for human use released for consultation january 2000 note for guidance on comparability of medicinal products containing biotechnology-derived proteins as active substances released for consultation may 2000 position statement on the use of tumorigenic cells of human origin for the production of biological and biotechnological medicinal products released for consultation july 2000 revision of section 3.2.5 of cpmp note for guidance on plasma-derived medicinal products released for consultation july 2000 points to consider on the reduction, elimination or substitution of thiomersal in vaccines released for consultation november 2000